Back to search results

Continuous Glucose Monitoring After Hospital Discharge for Diabetes

This study is looking at how continuous glucose monitors (CGMs) like the Libre 3 Plus and Dexcom G7 can help people with Type 1 or Type 2 diabetes manage their blood sugar after leaving the hospital. We want to see if using these devices improves your satisfaction with your diabetes care and your understanding of how to monitor your blood sugar. You might be able to join if you are an adult (18 or older) admitted to VUMC with high blood sugar (hyperglycemia) that required insulin during your hospital stay and at discharge. The study will measure your satisfaction and opinions through questionnaires 2-3 weeks after you leave the hospital. The study plans to enroll 60 participants, but its current status is unclear.

Study design
This study is designed to test two different continuous glucose monitors in 60 participants. It is an interventional study, meaning participants will receive one of the devices.
What's involved
Participants will start using either the Libre 3 Plus or Dexcom G7 continuous glucose monitor. You will complete questionnaires from enrollment until a follow-up telephone visit 2-3 weeks after discharge.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 2-3 weeks after hospital discharge, with questionnaires completed during this time.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06852950

Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge

Recruiting
NAAges 18+Interventional
Vanderbilt University Medical Center
~60 participants
Updated 2026-03-05 on ClinicalTrials.gov
What's tested:Libre 3 Plus Continuous Glucose MonitorDexcom G7 Continuous Glucose Monitor

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Questionnaire responses regarding patient satisfaction and opinion regarding use of continuous glucose monitoring system
Measured over From enrollment until follow-up telephone visit 2-3 weeks after discharge
+2 more outcomes measured

Conditions

Type 2 Diabetes Mellitus (T2DM)
Type 1 Diabetes Mellitus (T1DM)
Hyperglycemia

Explore related trials

HyperglycemiaType 1 Diabetes MellitusType 2 Diabetes Mellitus

Where it's being run

1 sites across 1 states
Tennessee1

Who to contact

Angel Morvant, MD
[email protected]
615-343-8332
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Non-pregnant adults, ages greater than or equal to 18 years, admitted to VUMC
Able to give informed consent
Hyperglycemia requiring insulin therapy including subcutaneous insulin injection or continuous subcutaneous insulin infusion (patient's own insulin pump) during hospitalization and at the time of discharge
POC glucose or venous glucose levels in the 24 hours prior to participation need to be 70-350 mg/dL
Need glucose readings greater than or equal to one time per day
Mental status and dexterity adequate to use Libre 3 Plus or Dexcom G7 sensors with Libre 3 or Dexcom G7 application on patient's smartphone

Exclusion

Currently using Libre 3 Plus or Dexcom G7 CGMS during hospitalization or have used Libre 3 Plus or Dexcom G7 CGMS in the past 3 months
Does not have smartphone compatible with Libre 3 App or Dexcom G7 App
Received chemotherapy during current hospitalization
Planning on major surgery within 10-15 days
Hemodialysis or peritoneal dialysis
Requiring vasopressors, intubation, sedation, or admission to an intensive care unit
Vitamin C use of more than 500 milligrams per day
Hydroxyurea use
Acetaminophen use of more than 4 grams per day or 1 gram every 6 hours
Significant pitting edema (3+ or greater) i.e. cirrhosis with ascites, congestive heart failure with edema, nephrotic syndrome, or signs of poor perfusion
Presentation in diabetic ketoacidosis or hyperosmotic nonketotic state
Skin allergy to adhesives

What this trial measures

  • Questionnaire responses regarding patient satisfaction and opinion regarding use of continuous glucose monitoring systemFrom enrollment until follow-up telephone visit 2-3 weeks after discharge

    Questionnaire responses regarding patient satisfaction and opinion regarding use of continuous glucose monitoring system: regarding how do subjects feel that using CGM impacted their glucose control on a scale of 1-5, with 1=strongly made it worse, 2=somewhat made it worse, 3=did not make it better or worse, 4=somewhat made it better, and 5=strongly made it better?; regarding what is the overall opinion of subject's experience with CGM use on a scale of 1-5, with 1=very negative, 2=negative, 3=neutral, 4=positive, 5=very positive.

  • Questionnaire responses regarding patient satisfaction and opinion regarding quality of diabetes careFrom enrollment until follow-up telephone visit 2-3 weeks after discharge

    Questionnaire responses regarding patient satisfaction and opinion regarding quality of diabetes care: regarding how do subjects feel that using CGM impacted the diabetes care overall on a scale of 1-5, with 1=strongly made it worse, 2=somewhat made it worse, 3=did not make it better or worse, 4=somewhat made it better, and 5=strongly made it better.

  • Questionnaire responses regarding patient familiarity with continuous glucose monitoringFrom enrollment until follow-up telephone visit 2-3 weeks after discharge

    Questionnaire responses regarding patient familiarity with continuous glucose monitoring: regarding degree of familiarity of CGMs in general and the different types of information provided by CGMs, what is the subject's familiarity on a scale of 1-5, with 1=very unfamiliar, 2=unfamiliar, 3=neutral, 4=familiar, 5=very familiar.